|
About us
|
How we regulate
|
Safety information
|
Committees
|
Conferences & Learning Centre |
Online services
|
Publications
|
News Centre
|
Your views
|
Main navigation 
Section search
Enter a keyword or phrase to search all pages in this section:
Advanced searchArchive:
Looking for a previously published document in this section?
Selective Serotonin Reuptake Inhibitors (SSRIs): Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data
Level 1 - Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents
Introduction
We have arranged this section into three levels of detail which we hope you will find useful:
› Level 1: Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents.
› Level 2: Summary of available safety and efficacy data in MDD in children and adolescents.
› Level 3: Summary of clinical trials relating to MDD in children and adolescents
Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents
| Fluoxetine | Sertraline | Citalopram | Escitalopram | Fluvoxamine | Paroxetine | Venlafaxine | Mirtazapine | |
|---|---|---|---|---|---|---|---|---|
|
Drug class |
SSRI |
SSRI |
SSRI |
SSRI (active constituent of citalopram) |
SSRI |
SSRI |
Serotonin and noradrenaline reuptake inhibitor (SNRI) |
Noradrenergic and specific serotonergic antidepressant |
|
Licensed indications children and adolescents |
None |
Obsessive compulsive disorder |
None |
None |
Obsessive compulsive disorder |
None |
None |
None |
|
Efficacy in major depressive disorder (MDD) in children and adolescents |
Demonstrated in controlled clinical trials |
Not demonstrated in controlled clinical trials |
Not consistently demonstrated in controlled clinical trials |
No data from clinical trials |
No data from clinical trials |
Not demonstrated in controlled clinical trials |
Not demonstrated in controlled clinical trials |
Not demonstrated in controlled clinical trials |
|
Safety profile in MDD trials in children and adolescents |
Mania and hypomania more frequently reported than in adults, perhaps as a result of differing inclusion criteria in clinical trials. No increased rate of self-harm and suicidal thoughts compared with placebo |
Rate of events including agitation, anorexia, insomnia and suicidal thoughts and self harm increased compared with placebo |
Increased rate of self-harm compared with placebo in 1 of 2 trials |
No data from clinical trials |
No data from clinical trials |
Increased rate of self-harm and suicidal thoughts compared with placebo |
Increased rate of self-harm and suicidal thoughts compared with placebo |
No increased rate of self-harm and suicidal thoughts compared with placebo |
|
CSM advice in relation to MDD in children and adolescents |
Risk/benefit balance is favourable |
Risk/benefit balance is unfavourable |
Risk/benefit balance is unfavourable |
Risk/benefit balance is presumed unfavourable. (Extrapolation from citalopram.) |
Risk/benefit balance is not assessable - safety and efficacy in adults cannot be extrapolated to under 18 year olds |
Risk/benefit balance is unfavourable |
Risk/benefit balance is unfavourable |
Risk/benefit balance is unfavourable |
Page last modified:
29 September 2005
© 2008 Crown Copyright Terms and conditions Links Freedom of information Report a suspected safety problem E-mail alerting service MHRA Portal
General enquiries: 020 7084 2000 info@mhra.gsi.gov.uk
To contact us about this website, use our feedback form.